Inhibrx takes a second shot at an IPO — this time bumping the goal to $100M-plus
La Jolla, CA-based Inhibrx couldn’t get their $75 million IPO over the goal line last year. But with the fervor for new biotech filings seemingly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
